11 citations
,
August 2014 in “Current Urology Reports” This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.
1 citations
,
April 2019 in “Clinical Breast Cancer” This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.
14 citations
,
November 2006 in “Current Medicinal Chemistry” This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.
24 citations
,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” This review examines hormonal influences on acne development and available hormonal therapies but reports no new clinical results.
19 citations
,
April 2020 in “Dermatologic Therapy” This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.